 | Up a level |
Veyrard, P; Pellet, G; Laharie, D; Nachury, M; Juillerat, P; Roblin, X (2023). Efficacy of induction therapy with calcineurin inhibitors in combination with ustekinumab for acute severe ulcerative colitis. Clinical gastroenterology and hepatology, 21(5), 1354-1355.e2. Elsevier 10.1016/j.cgh.2022.03.008
Juillerat, P; Schneeweiss, S; Cook, E F; Ananthakrishnan, A N; Mogun, H; Korzenik, J R (2012). Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease. Alimentary pharmacology & therapeutics, 36(3), pp. 239-47. Oxford: Wiley-Blackwell 10.1111/j.1365-2036.2012.05173.x
Juillerat, P; Wasan, SK; Fowler, SA; Yajnik, V; Korzenik, JR; Pabby, VK; Friedman, S; Coukos, JA; Barto, AE; Pellish, R; and Farraye, FA (2012). Efficacy and Safety of Natalizumab in Crohn’s Disease Patients Treated at 5 Academic Hospitals. Journal of Crohn's & Colitis, 6(Supplement 1), p. 128. Amsterdam: Elsevier
Juillerat, P (2012). Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. ECCO news, 7(1) Wien: European Crohn's and Colitis Organisation ECCO
Juillerat, P; Schneeweiss, S; Mogun, H; Cook, EF; Ananthakrishnan, AN; Korzenik, JR (2011). New H2-eceptor Antagonist Use May Increase Risk of Surgery or Hospitalization in Crohn's Disease While PPI Use May Be Associated With Ulcerative Colitis Flares. Differential Effects of Acid Suppressing Agents in IBD. In: Digestive Disease Week.
Juillerat, P; Schneeweiss, S; Cook, F; Ananthakrishnan, A; Mogun, H; Korzenik, J (2011). Gastric Acid Inhibiting Medications May Alter The Course Of Inflammatory Bowel Disease. In: 19th United European Gastroenterology Week (UEGW). Stockholm, Sweden. October 22-26, 2011.
Pittet, V; Juillerat, P; Michetti, P; Vader, J-P; Burnand, B; Rogler, G; Beglinger, C; Seibold, F; Mottet, C; Felley, C; Gonvers, J-J; Froehlich, F; Swiss IBD Cohort Study Group, The (2010). Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Alimentary pharmacology & therapeutics, 32(8), pp. 1007-16. Oxford: Wiley-Blackwell 10.1111/j.1365-2036.2010.04434.x
Camara, RJ; Juillerat, P; Pittet, V; Schoepfer, AM; Begré, S; von Känel, R (2010). Psychological stress predicting adverse events in Cohn's disease. Psychosomatic medicine, 2010(72), A34. Baltimore, Md.: Lippincott Williams & Wilkins
Camara, RJ; Juillerat, P; Pittet, V; Schoepfer, AM; Begré, S; von Känel, R (2010). Quality of life predicting adverse events in Crohn's disease. Psychosomatic medicine, 2010(72), A34. Baltimore, Md.: Lippincott Williams & Wilkins
Pittet, V; Juillerat, P; Mottet, C; Felley, C; Ballabeni, P; Burnand, B; Michetti, P; Vader, JP; and, the Swiss IBD Cohort Study Group (2009). Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). International journal of epidemiology, 38(4), pp. 922-31. Oxford: Oxford University Press 10.1093/ije/dyn180
